Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22472933 | 0.88 | HPGD (0.44) | ALDH1A1CHRM1TSHRPOLBHPGD | |
| SCHEMBL22472905 | 0.84 | ALDH1A1 (0.53) | ALDH1A1CHRM1TSHRMAPTPOLB | |
| SCHEMBL21597928 | 0.84 | MAPT (0.48) | ALDH1A1CHRM1MAPTKMT2A | |
| SCHEMBL20585539 | 0.83 | CHRM1 (0.44) | ALDH1A1CHRM1TSHRMAPK1 | |
| SCHEMBL20584844 | 0.83 | CHRM1 (0.44) | ALDH1A1CHRM1TSHRMAPK1 | |
| SCHEMBL20584845 | 0.83 | CHRM1 (0.44) | ALDH1A1CHRM1TSHRMAPK1 | |
| SCHEMBL20585541 | 0.83 | CHRM1 (0.44) | ALDH1A1CHRM1TSHRMAPK1 | |
| SCHEMBL20584847 | 0.83 | CHRM1 (0.44) | ALDH1A1CHRM1TSHRMAPK1 | |
| SCHEMBL20585540 | 0.83 | CHRM1 (0.44) | ALDH1A1CHRM1TSHRMAPK1 | |
| SCHEMBL27176073 | 0.83 | HPGD (0.47) | ALDH1A1TSHRHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810614-B1 | BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2024-03-27 | — | — | EP | claimed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | claimed |
| EP-3810614-A1 | BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | Heptares Therapeutics Limited (GB) | 2021-04-28 | — | — | EP | claimed |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-01-07 | — | — | US | claimed |
| WO-2019243851-A1 | BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-12-26 | — | — | WO | claimed |
| EP-3810614-B1 | BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-01-07 | — | — | US | disclosed |
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773090-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | ALDH1A1 2016/4885CHRM1 1/4885TSHR 79/4885 |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | ALDH1A1 2016/4885CHRM1 1/4885TSHR 79/4885 |
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | ALDH1A1 2016/4885CHRM1 1/4885TSHR 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.